Genprex appoints Dr. Mark Berger as CMO, Dr. Hemant Kumar as CTO; COO Redman's role reduced

Genprex, Inc.

Mark Berger, MD appointed Chief Medical Officer; Hemant Kumar, PhD appointed Chief Manufacturing and Technology Officer.
Michael Redman, EVP and COO, no longer oversees clinical and manufacturing operations; company in discussions for alternate role.
Appointments effective September 2021 as disclosed in prior 8-K filed September 28, 2021.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Michael Redman

Executive Vice President and Chief Operating Officer

GNPX · Genprex, Inc.

Filed: September 29, 2021, 7:59 PM ET

With these new appointments, Michael Redman, the Company’s Executive Vice President and Chief Operating Officer is no longer overseeing the Company’s clinical and manufacturing operations.

Appointed

Hemant Kumar

Chief Manufacturing and Technology Officer

GNPX · Genprex, Inc.

Effective: 2021-09-28
Filed: September 29, 2021, 7:59 PM ET

the Company has appointed Mark Berger, MD and Hemant Kumar, PhD as its new Chief Medical Officer and new Chief Manufacturing and Technology Officer, respectively.

Appointed

Mark Berger

Chief Medical Officer

GNPX · Genprex, Inc.

Effective: 2021-09-28
Filed: September 29, 2021, 7:59 PM ET

the Company has appointed Mark Berger, MD and Hemant Kumar, PhD as its new Chief Medical Officer and new Chief Manufacturing and Technology Officer, respectively.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Redman changed role as Executive Vice President and Chief Operating Officer at Genprex, Inc..

Action: reassigned
Role: Executive Vice President and Chief Operating Officer

Exact text from the filing

With these new appointments, Michael Redman, the Company’s Executive Vice President and Chief Operating Officer is no longer overseeing the Company’s clinical and manufacturing operations.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Hemant Kumar was appointed as Chief Manufacturing and Technology Officer at Genprex, Inc..

Action: appointed
Role: Chief Manufacturing and Technology Officer

Exact text from the filing

the Company has appointed Mark Berger, MD and Hemant Kumar, PhD as its new Chief Medical Officer and new Chief Manufacturing and Technology Officer, respectively.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Mark Berger was appointed as Chief Medical Officer at Genprex, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

the Company has appointed Mark Berger, MD and Hemant Kumar, PhD as its new Chief Medical Officer and new Chief Manufacturing and Technology Officer, respectively.

View on SEC.gov

Genprex, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-21-022843

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.